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The development of high-throughput screening methods such as array-based comparative genome hybridization
(array CGH) allows screening of the human genome for copy-number changes. Current array CGH strategies have
limits of resolution that make detection of small (less than a few tens of kilobases) gains or losses of genomic DNA
difficult to identify. We report here a significant improvement in the resolution of array CGH, with the development
of an array platform that utilizes single-stranded DNA array elements to accurately measure copy-number changes
of individual exons in the human genome. Using this technology, we screened 31 patient samples across an array
containing a total of 162 exons for five disease genes and detected copy-number changes, ranging from whole-gene
deletions and duplications to single-exon deletions and duplications, in 100% of the cases. Our data demonstrate
that it is possible to screen the human genome for copy-number changes with array CGH at a resolution that is
2 orders of magnitude higher than that previously reported.
Introduction
The extent to which genomic copy-number polymor-
phisms (CNPs) contribute to human genetic diversity is
not known. Recent studies have demonstrated the pres-
ence of CNPs, a proportion of which encompass genes,
in the genomes of normal individuals (Iafrate et al. 2004;
Sebat et al. 2004). This suggests that these variants may
be important in our understanding of phenotypic varia-
tion or may predispose to or directly cause disease. On
the basis of current knowledge, ∼5%–6% of gene mu-
tations that are causative of inherited disorders are copy-
number changes defined as gross deletions or duplica-
tions (Armour et al. 2002), although this frequency may
represent an underestimate. These disease-causing copy-
number changes can range in size from 100 bp to several
megabases and can encompass as little as a single exon
and as much as entire genes or several genes.
The ability to detect CNPs and pathogenic chro-
mosomal imbalances has been dramatically improved
through the use of array-based comparative genome hy-
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bridization (array CGH) (Solinas-Toldo et al. 1997; Pin-
kel et al. 1998). Array CGH offers high sensitivity and
dynamic range to quantitatively measure from single
copy-number losses or gains to high copy-number am-
plifications, as well as sufficient resolution and scalabili-
ty for complete genomewide scans (Snijders et al. 2001;
Fiegler et al. 2003; Vissers et al. 2003; Iafrate et al.
2004; Inazawa et al. 2004; Ishkanian et al. 2004). Cur-
rently, the most robust array CGH approaches utilize
large genomic clone inserts as array elements but have
a maximum resolution of ∼40–50 kb (Albertson and
Pinkel 2003; Snijders et al. 2003; Mantripragada et al.
2004a). The use of oligonucleotides (Lucito et al. 2000,
2003; Bignell et al. 2004; Carvalho et al. 2004; Sebat
et al. 2004), cDNA clones (Pollack et al. 1999, 2002;
Heiskanen et al. 2000), or sequence-defined PCR prod-
ucts (Mantripragada et al. 2003, 2004b) for array CGH
allow this resolution to be theoretically increased solely
on the basis of the size of the genomic region covered
by the array element. However, because of limitations
of the technologies, the effective resolution for these
methods is no greater than 15–30 kb, since they rely
on averaging measurements taken from multiple array
elements, pooling PCR products to be spotted as single
array elements, or reducing the complexity of the human
genome to detect and quantitate copy-number changes.
Therefore, it has not yet been demonstrated that array
elements covering small regions of the genome can de-
liver substantially higher resolution than that of large
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genomic clone array CGH to identify small genomic
deletions and duplications (100 bp to 15 kb).
The ability to detect copy-number changes encom-
passing such small regions of the genome has thus far
been achievable only by using other types of molecular
assays. Apart from the more traditional approaches of
Southern analysis, FISH, and quantitative PCR (Armour
et al. 2002), more-recent approaches have included the
development of multiplex amplifiable probe hybridiza-
tion (MAPH) (Armour et al. 2000; Sellner and Taylor
2004) and the multiplex ligation-dependent probe am-
plification (MLPA) (Schouten et al. 2002; Sellner and
Taylor 2004). For MAPH and MLPA, the resolution is
at the level of individual exons, and they are becoming
widely used as research and diagnostic tools, with very
high reliability for identifying and quantitating copy-
number changes in human disease genes (White et al.
2002, 2003, 2004; Akrami et al. 2003; Sellner and Tay-
lor 2004). However, because both methods rely on mul-
tiplexing, the number of measurements obtainable from
a single assay is limited. Therefore, the development of
approaches that provide robust measurement precision
of copy-number changes, scalability, and very high reso-
lution have thus far been unavailable in the field of
human molecular genetics.
We describe here an array CGH–based approach that
addresses all of these issues for the analysis of copy-
number changes in the human genome. We have de-
veloped an array platform that allows single strands of
DNA derived from double-stranded PCR products to
be retained on the surface of a slide through the use of
5′-aminolink chemistry. This platform improves the sig-
nal:noise ratio, such that it is possible to detect indi-
vidual exons in the human genome and to quantify their
copy number accurately. We refer to this method as
“exon array CGH.” To demonstrate the utility of the
approach, we constructed an array containing 162 ex-
ons that collectively span five human genes (COL4A5
[MIM 303630], DMD [MIM 300377], NF2 [MIM
607379], PLP1 [MIM 300401], and PMP22 [MIM
601097]) involved in inherited genetic disorders (see
table 1). We have analyzed a series of 31 DNA samples
from patients affected with these disorders and have
characterized copy-number changes that have been val-
idated with other molecular methods for all 31 samples.
Our method is 2 orders of magnitude more sensitive
than other forms of array CGH and provides resolution
and accuracy that are similar to other current methods
of screening genes for copy-number changes at the level
of the exon. Since exon array CGH is completely scal-
able, this new molecular tool will provide the means for
researchers to screen the human genome at high resolu-
tion to identify and annotate novel CNPs and causative
mutations in normal and disease states, respectively, as
well as to facilitate array-based applications to study
other aspects of genome biology.
Material and Methods
PCR Amplification and Microarray Fabrication
Primers pairs for exons of the COL4A5, DMD, NF2,
PLP1, and PMP22 genes (table 2); for amplicons covering
the 3′ UTRs of genes on chromosome 22 (normalization
controls); and for other amplicons used here were ob-
tained from primer sets published elsewhere (Strautnieks
et al. 1992; Plant et al. 1999; Leiden University Medical
Center Web site) or were designed using the relevant
genomic sequence and the Primer3 software and Web
site (Rozen and Skaletsky 2000; Whitehead Institute).
All amplicons used in the present study were repeat free.
When possible, primer pairs were designed or obtained
for each exon and, ideally, were located in the upstream
and downstream intronic sequences flanking the exon.
In a few instances, however, primers were designed
within the exonic sequence. When two adjacent exons
were separated only by a very small intron, a single pair
of primers was designed to contain both exons. Primer
pairs and all amplicons sequences were compared with
the entire human genome sequence by use of e-PCR
(Schuler 1997) and BLASTN to identify any potential
cross-reacting DNA sequences. In cases in which the
PCR product for a given exon did not accurately or re-
producibly report copy-number values, additional PCR
assays were designed and tested on the array.
To generate arrays containing single-stranded array
elements, all PCR products used in the present study
were prepared as follows. To the 5′ end of the forward
primer of each pair was added an 8-bp universal se-
quence (5′-TGACCATG-3′). These primer pairs (final
concentration 0.5 mM) were used to amplify exon-con-
taining PCR products in a 20-ml final volume first-round
PCR containing 50 mM KCl, 5 mM Tris HCl (pH 8.5),
2.5 mM MgCl2, 10 mM dNTPs (Pharmacia), 0.625 U
Taq polymerase (Perkin Elmer–Cetus), and 50 ng of hu-
man genomic DNA. Thermocycling was optimized for
each primer pair by use of an annealing temperature of
50C–60C (cycling conditions available on request).
PCR products from these reactions were diluted 1:1000
and were used in second-round reactions containing the
5′-(C6) amino-modified universal primer 5′-GCTGAAC-
AGCTATGACCATG-3′ (Eurogentec) and the reverse
gene-specific primer of each set. Reaction conditions
were the same as those in the first round, except the
reaction volume was 60 ml. For the comparison of single-
versus double-stranded DNA array elements, the uni-
versal linker was also added to the 5′ end of the reverse
gene-specific primer. This allowed a 5′-aminolink to be
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Table 2
Primer Pairs Used to Amplify Exons for Array CGH
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
incorporated on either the forward or the reverse strand
in second-round reactions.
To prepare second-round PCR products for arraying,
spotting buffer was added at final concentrations of 0.25
M sodium phosphate buffer pH 8.5 and 0.00025% sar-
kosyl (BDH Laboratory Supplies). The PCR products
were then filtered through multiscreen-GV 96-well filter
plates (Millipore), were aliquoted into 384-well plates
(Genetix), and were arrayed onto Codelink slides (Amer-
sham) in quadruplicate in a 16-block format by use of
a Microgrid II arrayer (Biorobotics/Genomic Solutions).
Slides were processed to generate single-stranded array
elements, as described on the Sanger Institute microarray
Web pages, and were stored at room temperature until
hybridized.
Patient and Control DNA Samples
Thirty-one patient samples were obtained from a num-
ber of laboratories; all samples had been screened for
mutations in the relevant disease gene at accredited di-
agnostic laboratories. Samples from patients with mu-
tations in the COL4A5, DMD, and PMP22 genes were
obtained from the Southeast Thames Regional Genetics
Centre (at King’s, Guy’s, and St. Thomas’s Hospitals,
London). These samples were all made anonymous for
inclusion in this study. DNA samples from patients with
NF2 mutations were obtained from the Department of
Genetics and Pathology at Uppsala University. DNA sam-
ples from patients with mutations in the PLP1 gene were
obtained from the Institute of Child Health (London);
additional patients with mutations in the PMP22 gene
were obtained from the Center for Human Genetics
(Leuven). Control DNA was obtained from archives of
normal male and female DNA housed at the Sanger In-
stitute (Cambridge). DNA was extracted using a variety
of standard methods (salt/chloroform, phenol, commer-
cial kits, etc.) from either peripheral blood or cultured
cell lines. Aliquots of patient and control DNA samples
were quantitated using a fluorometer (TD-360 [Turner]),
were sonicated to an average size of ∼10 kb by use of
a water-bath sonicator (VirSonic 300 [Virtis]), and were
visualized by agarose-gel electrophoresis. Female and
male pool DNA samples that were used as reference DNA
controls were derived by combining equal amounts of
peripheral blood DNA from five females and five males,
respectively. Male (XY) and female (XX) lymphoblas-
toid cell lines were also used as controls in the validation
experiments. None of the control samples had mutations
in the genes analyzed in this study.
Fluorescent DNA Labeling, Microarray Hybridization,
and Data Analysis
Fluorescent-labeled DNA samples were prepared us-
ing a modified Bioprime labeling kit (Invitrogen) in 100-
ml reaction volumes containing 600 ng genomic DNA,
dNTPs (0.2 mM dATP, 0.2 mM dTTP, 0.2 mM dGTP,
and 0.05 mM dCTP), and 0.04 mM Cy5/Cy3 dCTP (GE
Healthcare). Reference control samples were labeled with
Cy3, and test samples were labeled with Cy5. Labeling
reactions were purified using Micro-spin G50 columns
(Pharmacia-Amersham) in accordance with the manu-
facturer’s instructions. Reference and test samples were
combined and precipitated with 3 M sodium acetate (pH
5.2) in 2.5 volumes of ethanol with 90 mg human Cot
DNA (Invitrogen). The DNA pellet was resuspended in
hybridization buffer containing 50% deionized forma-
mide, 10% dextran sulphate, 10 mM Tris-HCl (pH 7.4),
2# SSC, 0.1% Tween-20, and 300 mg yeast tRNA (In-
vitrogen). Similarly, the prehybridization mixture was
prepared by precipitating 400 mg herring sperm DNA
(Sigma) and 67.5 mg human Cot DNA with 3 M sodium
acetate (pH 5.2) and 2.5 volumes of ethanol; this DNA
pellet was resuspended in the same hybridization buffer
but with no yeast tRNA included.
Microarrays were prehybridized, hybridized, and
washed using methods described elsewhere (Fiegler et
al. 2003). Microarrays were scanned using a ScanArray
4000 confocal laser-based scanner (Perkin Elmer). Mean
spot intensities from images were quantified using Quant-
Array or ScanArray Express (Perkin Elmer) with back-
ground subtraction. Mean ratios and SDs for all exon
PCR products in quadruplicate were calculated, and the
mean exon ratios were normalized to the chromosome
22 control element mean ratios for each of the 16 blocks
independently to within 2% of the theoretical value
( ). Ratios were obtained for each exon in-1.00 0.02
dependently, except in the cases in which more than one
exon was contained in a single PCR product. Further-
more, there was no averaging of copy-number data for
exons found in different PCR products. Although some
exons were represented by more than one PCR product,
the data from only the array element that most accu-
rately reported copy number (i.e., that behaved closest
to the theoretical values) were retained in the final data
set for each sample in all but two instances—for the
PMP22 gene, the data from two PCR products repre-
senting exon 1 were pooled to derive a mean exon 1
ratio for both products. Similarly, this procedure was
also performed for PMP22 exon 5. To visualize the data,
the final data set of mean ratios was plotted on a his-
togram for each exon or exon pair of COL4A5, DMD,
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NF2, PLP1, and PMP22. Microarray experiments with
control samples and patient samples were performed—
multiple times, in some cases—to determine the repro-
ducibility of the method. However, the derived mean-
ratio data were determined for each hybridization ex-
periment rather than from pooling of data from multiple
experiments. For single- versus double-stranded DNA
comparisons, mean intensities of quadruplicate spots
were calculated with background subtraction in a single
channel.
Results
Single-Stranded Technology Allows Detection
of Exon-Sized Array Elements
One of the main considerations for array CGH is re-
lated to the complexity of the genome, as well as how
this complexity is reflected in the signal measurements
from which the copy-number changes are derived. Given
that a typical exon in the human genome (median and
mean sizes of 133 bp and 262 bp, respectively) represents
a segment of genomic DNA found at a level of 1–2 in
sequence equivalents in the diploid human ge-74# 10
nome, it was necessary to address how to detect such a
sequence at this level without reducing genome com-
plexity or compromising the accuracy of the measure-
ments. To this end, we developed an array system that
allows single strands of DNA derived from double-
stranded PCR products to be retained on the surface of
the microarray slide. By incorporating a 5′-aminolink
modification onto the end of one strand of a double-
stranded DNA molecule during PCR, it is possible to
covalently attach this strand to the surface of the slide,
and the unmodified strand can be removed (fig. 1). Since
single-stranded array elements cannot reanneal to form
duplex molecules, we anticipated an increase in the signal:
noise ratio in array CGH experiments, since there would
be more single-stranded DNA on the surface of the slide
capable of hybridizing with labeled sample. We demon-
strated increased signal:noise measurements for single-
stranded array elements (fig. 1). Test arrays were printed
with array elements on which 5′-aminolink modifica-
tions were incorporated on either one or both strands.
For a series of genomic array elements of 200–400 bp
in size that we tested in hybridizations with fluorescently
labeled human genomic DNA, single-stranded elements
provided an increased signal:noise ratio, with a range
of 1.16–2.51-fold increase, depending on the array ele-
ment. On average, this translated into a 1.79-fold in-
crease in the signal:noise ratio. We had previously dem-
onstrated a similar increase in the signal:noise ratio for
cDNA expression analysis (C.L. and D.V., unpublished
data). Thus, this array platform facilitated increased
signal:noise ratios and thereby provided evidence that
we could improve the signal sufficiently to detect human
genomic DNA sequences at the resolution of single exons.
Assessing the Performance of DNA Elements on Exon
Arrays
We generated an exon array that included a set of array
elements designed for every exon of five genes. The five
genes included on this array were chosen to assess tech-
nical aspects of the technology and to demonstrate its
clinical relevance (table 1) (Atkin et al. 1988; Worton
and Thompson 1988; Den Dunnen et al. 1989; Gillard
et al. 1989; Nelis et al. 1996; Heim et al. 1997; Lemmink
et al. 1997; Sistermans et al. 1998; Mimault et al. 1999;
Plant et al. 1999; Rautenstrauss et al. 2000; Bruder et al.
2001). These were the X-linked genes COL4A5, DMD,
and PLP1 and the autosomal genes NF2 and PMP22.
Mutations and/or copy-number changes in these five
genes result in human inherited disorders. For the 162
exons of these genes, 158 array elements were initially
designed and spotted on our arrays. We included a sec-
ond array element for each of 18 exons that we chose
at random to help assess sequence context on reporting
accuracy, which brought the total number of array ele-
ments for these genes to 176. From the 3′ UTRs of genes
on chromosome 22, 360 repeat-free amplicons were also
spotted on these arrays and were used as normalization
controls. These controls were, on average, of a size simi-
lar to that of the exon elements. We performed a series
of validation experiments of male (XY) versus female
(XX), and female (XX) versus female (XX) competitive
hybridizations across a series of five batches of array
printed at different times, with elements printed in quad-
ruplicate, to assess the performance of the exon array
in measuring copy-number changes. From the initial
minimal set of 158 array elements, 135 (85.4%) reported
copy-number measurements that were within 0.15 copy-
number units of the theoretical values. The second array
element for each of the 18 exons that had two different
elements on the array showed a similar success rate (16
[88.9%] of 18). To obtain accurate copy-number mea-
surements for all remaining exons in the five genes, we
designed and tested a second element for each of 23
exons, 2 of which required a third iteration of design.
These redesigned elements replaced the original elements
for those exons in all subsequent analyses. In total, we
analyzed 201 array elements, 174 (86.6%) of which re-
ported accurate copy-number measurements and had a
size range of 139–571 bp. On the basis of these exper-
iments, we demonstrated that we could obtain accurate
copy-number measurements for ∼85% of the exons in
our study by designing a single array element and for
100% of all exons by designing a second or, in a small
minority of cases, a third array element. Typical ex-
amples of the quality of the data that we obtained from
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Figure 1 Development of single-stranded array platform for exon array CGH. Schematic diagram shows the approach adopted to make
single-stranded PCR products with the increased sensitivity on the array platform described in this article. A, Oligonucleotide containing a 5′-
C6-aminolink modification (gray ball) used as a primer (short green bar) on a genomic DNA or PCR template strand (red wavy line) in a PCR
reaction. B and C, Synthesized double-stranded PCR product containing the 5′-aminolink modification on one strand only. Newly synthesized
strand containing the 5′-aminolink modification is shown as a green dotted/solid line. D, PCR product spotted onto the microarray slide. E,
Covalent attachment to the surface formed through the 5′-aminolink modification by subjecting the slide to high humidity. F, Removal of reverse
strand that is not covalently attached to the surface of the slide by use of physical and chemical denaturation. G, The resultant single-stranded
array element. H, Microarray image (gray scale) showing the results of fluorescently labeled genomic DNA hybridized to test arrays containing
single-stranded and double-stranded PCR products for a series of genomic array elements (“i–xii”) spotted in duplicate. Single-stranded elements
for either one strand (5′-aminolink on forward strand [lanes 1 and 2]) or the other strand (5′-aminolink on the reverse strand [lanes 5 and 6])
or for double-stranded elements (5′-aminolinks on both strands [lanes 3 and 4]) were prepared on the test array. Single-stranded elements gave
a higher signal for all genomic products (see the “Results” section).
these validation experiments for array elements covering
all 162 exons of the five genes are shown in figure 2.
The three X-linked genes (DMD, PLP1, and COL4A5)
showed easily discernible single copy-number differences
in XX versus XY validation experiments, when com-
pared with the two autosomal genes (PMP22 and NF2)
(fig. 2A). XX versus XX validation experiments also
showed the expected copy-number equivalence for all
genes (fig. 2B).
Across the validation experiments, signal:noise ratios
varied from hybridization to hybridization, which we
attributed to variations in cyanine dye quality, DNA
quality, labeling efficiencies, array batch, and other tech-
nical considerations. However, whereas signal:noise ra-
tio did not appear to dramatically affect the range of mean
copy-number values for each exon spotted in quadrupli-
cate, the accuracy of the measurements was noticeably
improved as the signal:noise ratio increased (fig. 2C).
SDs in the quadruplicate measurements made for each
exon showed a strong negative correlation with signal:
noise ratio ( ). This would suggest that therp 0.97
single-stranded array platform we have developed not
only helps to improve signal:noise ratio, but, as a con-
sequence, also reduces measurement error. More im-
portantly, our data also demonstrate that even exons
that exhibit an extremely low signal:noise ratio on our
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Figure 2 Validation experiments for exon arrays. A, Fluores-
cently labeled DNA derived from genomic DNA from a single male
(Cy5) hybridized on the exon array with that derived from five females
(used as a pool) (Cy3). The plot shows the Cy5 channel:Cy3 channel
ratios obtained for exons (represented as black dots) for COL4A5,
DMD, NF2, PLP1, and PMP22. Each exon is plotted as a function
of its position 5′r3′ for each gene. The number of exon array elements
assayed for each gene is shown in parentheses below the gene name.
Exons for the three X-linked genes and the two autosomal genes
showed ratios centered around the theoretical values of 0.5 and 1,
respectively. B, Fluorescently labeled DNA derived from genomic DNA
from a single female (Cy5) hybridized on the exon array with that
derived from the female pool (Cy3). The plot shows the ratios obtained
for each exon, as described above (A), centered around the theoretical
value of 1. C, The effect of signal:noise ratio on measurement error
determined, using exon arrays, in 10 male versus female-pool vali-
dation experiments. The plot shows the relationship between mean
signal:noise and mean SD. Both means were derived as the mean of
all mean quadruplicate element measurements per experiment. The
black triangles represent each of the 10 male/female validation ex-
periments. The correlation coefficient (r) between mean SD and mean
signal:noise was 0.97.
array (i.e., in the range of 1–1.5) could be quantitated
accurately.
We studied further the performance of our single-
stranded array elements to identify other features that
may contribute to reporting accuracy in array CGH ex-
periments. Using regression analysis on data obtained
from all 201 exon array elements, we found no strong
correlations between the accuracy of copy-number mea-
surements and inherent features of the array elements,
such as GC content, length, melting temperature, sec-
ondary structure, similarity to other genomic sequences,
and distance from upstream or downstream repeat se-
quences in genomic DNA. However, given that we could
obtain accurate copy-number measurements for some
exons only by redesigning array elements, sequence con-
text is likely to contribute in some way to reporting
accuracy. We also assessed whether the location of an
element on the array affected reporting accuracy, by
spotting independent preparations of 12 of the array
elements in alternative locations on the array. All 12 of
these array elements reported accurate copy-number mea-
surements irrespective of their array coordinate. This evi-
dence, together with the rest of our empirical data, dem-
onstrates that, although it is unclear which factors may
influence the performance of DNA elements on our exon
array, this platform is robust within a variety of sequence
contexts and technical constraints.
Detection of Copy-Number Changes in Patient
Material
We further tested the performance of the exon array
and its potential application as a research and diagnostic
tool by detecting copy-number changes in DNA samples
from patients with inherited disorders. Thirty-one pa-
tient DNA samples (from 24 males and 7 females) were
collected that all had known pathogenic copy-number
changes in one of the five disease genes represented on
the array. We were able to determine copy-number
changes in all 31 DNA samples and with equal efficacy
in affected males, affected females, and nonsymptomatic
carrier females (for X-linked disorders). All of these re-
sults were in agreement with the molecular data deter-
mined elsewhere for these patients (Ellis and Malcolm
1994; Harding et al. 1995; Woodward et al. 1998, 2000;
Bruder et al. 2001; Buckley et al. 2002; Mantripragada
et al. 2003; S.A., unpublished data; J.R.V., unpublished
data) or as part of the present study. Our results are
summarized in table 3 and figure 3. In total, we detected
copy-number changes (either a gain or loss) in patient
samples for 121 of the 158 array elements containing
exons that were present on the array. The demonstrated
copy-number changes included 10 whole-gene deletions
(fig. 3A), 8 whole-gene duplications (fig. 3B), 2 whole-
gene triplications (fig. 3C and 3D), 3 partial-gene du-
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Table 3
Copy-Number Changes Detected in 31 Patient Samples
Sample Patient Reference Sex Gene Affected Mutation
1 JPa,b,c Male NF2 Whole-gene deletion
2 p7a,b Male NF2 Whole-gene deletion
3 p130b Male NF2 Deletion (exons 13–15)
4 EA01(241397) Male PMP22 Whole-gene deletion
5 EA02(260055) Female PMP22 Whole-gene deletion
6 EA03(218861) Male PMP22 Whole-gene deletion
7 EA04(268266) Male PMP22 Whole-gene deletion
8 EA05(251650) Male PMP22 Whole-gene deletion
9 EA06(263902) Female PMP22 Whole-gene duplication
10 EA07(221358) Male PMP22 Whole-gene duplication
11 EA08(138116) Male PMP22 Whole-gene duplication
12 EA09(231345) Male PMP22 Whole-gene duplication
13 EA10(271065) Male PMP22 Whole-gene duplication
14 EA11 Male COL4A5 Whole-gene deletion
15 EA12 Male DMD Deletion (exon 51)
16 EA13 Male DMD Deletion (exon 44)
17 EA14 Male DMD Deletion (exons 3–7)
18 EA15 Female PMP22 Whole-gene deletion
19 EA16 Male PMP22 Whole-gene deletion
20 EA17 Male DMD Deletion (exons 45–52)
21 EA18 Female DMD Deletion (exons 45–48)
22 EA19 Male DMD Duplication (exon 2)
23 EA20 Female DMD Deletion (exons 17–48)
24 EA21 Male DMD Deletion (exons 45–50)
25 EA22 Male DMD Duplication (exons 2–7)
26 EA23 Male DMD Duplication (exon 3)
27 DH/PMD2-1d,e,f Male PLP1 Whole-gene triplication
28 PMD2-2d,e,f Female PLP1 Whole-gene triplication
29 NO/PMD9-1d,f Male PLP1 Whole-gene duplication
30 PMD4-2f Female PLP1 Whole-gene duplication
31 PMD4-1f Male PLP1 Whole-gene duplication
NOTE.—Copy-number changes in a collection of 31 patient samples found using
the exon array described in the present study. Where relevant, patient references have
been included from other published studies.
a Mantripragada et al. 2003.
b Bruder et al. 2001.
c Buckley et al. 2002.
d Ellis and Malcolm 1994; Woodward et al. 1998.
e Harding et al. 1995.
f Woodward et al. 2000.
plications (fig. 3E), and 8 partial-gene deletions (fig. 3F,
3G, and 3H).
In the DNA sample of one patient (patient EA11), in
which the entire COL4A5 gene was deleted, we detected
a copy-number measurement in COL4A5 exon 1 (0.26)
that did not suggest a complete absence of this exon
(theoretical value of 0). The PCR product for this exon
showed an 86% sequence similarity across 212 bp to a
sequence on the short arm of chromosome X. This was
the highest degree of sequence similarity found for any
of the elements on the exon array. Therefore, although
exon 1 was completely deleted in patient EA11 (as con-
firmed by PCR), the cross-hybridizing X-linked sequence
was being reported by the exon 1 array element.
Of the 11 partial-gene duplications/deletions, 4 in-
volved only a single exon, 1 of which was a single-copy
number gain of DMD exon 2 (fig. 3E). The array ele-
ment for DMD exon 2 displayed the lowest signal:noise
ratio across all array CGH experiments performed for
the present study. This not only helps demonstrate the
sensitivity of the array system and our ability to quan-
titate weak signals, but it also shows the utility of the
array for accurate prediction of copy-number changes
involving only DMD exon 2; a single-exon duplication
of exon 2 is the most frequently occurring DMD muta-
tion, according to one study that used the MAPH assay
(White et al. 2002), but is also one of the most difficult
to determine using hybridization-based approaches, be-
cause it is highly AT rich (PCR product is 73.4% AT
rich) (White et al. 2002).
Discussion
We report here an array CGH platform that can measure
copy-number changes accurately at the resolution of sin-
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Figure 3 Exon copy-number changes in medically relevant disease genes. Representative results of exon array CGH for patient DNA
samples hybridized against a female pool that demonstrates the variety of copy-number changes detected in the present study. All patient samples
were fluorescently labeled using Cy5, and all control female-pool samples were fluorescently labeled using Cy3. The features of the plots are
as described for figure 2. The gray arrows highlight the copy-number changes. A, Female patient—EA02(260055)—with HNPP showing a
deletion of the entire PMP22 gene. B, Male patient—EA07(221358)—with CMT1 showing a duplication of the entire PMP22 gene. C, Male
patient (DH/PMD2–1) with PMD showing a triplication of the entire PLP1 gene. D, Female PMD carrier (PMD2–2, mother of patient in panel
C) showing a triplication of the entire PLP1 gene. E, Male patient (EA19) with DMD showing a duplication of exon 2 in the DMD gene. F,
Male patient (p130) with NF2 showing a deletion of exons 13–15 of the NF2 gene. G, Male patient (EA14) with DMD showing a deletion
of exons 3–7 of the DMD gene. Panel also shows the confirmatory PCR results; lanes are numbered according to the exons assayed and size
markers (“M”), in base pairs, shown at the left of the gel image. H, Male patient (EA12) with DMD showing the deletion of exon 51 of the
DMD gene. Confirmatory PCR is also shown with lanes numbered according to the exons assayed and size markers (“M”), in base pairs,
shown at the left.
gle exons. By developing an array system that results in
single-stranded DNA elements being bound to the sur-
face of a slide, we have demonstrated an improved
signal:noise ratio that facilitates the accuracy in copy-
number measurements for array elements in the size
range of 139–571 bp. We have further shown that con-
stitutionally inherited copy-number changes, as either de-
letions or duplications, were detected in 100% of patient
samples analyzed on an exon array containing array ele-
ments for 162 exons from five disease genes. The results
described here represent the first time, to our knowledge,
that array CGH has been shown to perform robustly at
the resolution of single exons. This represents an increase
in array CGH resolution that is 2 orders of magnitude
higher than has been reported elsewhere.
Our study provides compelling empirical evidence that
it will be possible to obtain accurate copy-number mea-
surements for virtually all exons in the genome, with
∼85% of exons requiring that a single-array element be
designed and tested and the remainder requiring that
additional array elements be validated in an iterative
process. Indeed, in the present study, we were able to
design array elements for 161 (99.4%) of 162 exons
that faithfully reported copy number in validation ex-
periments and in the analysis of patient samples. For
the one remaining exon, similarity with a cross-hybrid-
izing genomic sequence was an issue, which suggests
that this and possibly other sequence-based factors may
affect the performance of array elements for other exons
in the genome. What these factors are remains unclear.
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In some instances, it may be necessary to use “surro-
gate” exons—that is, array elements designed for se-
quences that lie adjacent to exons and that may perform
more robustly in array CGH. Averaging measurements
from multiple array elements may also provide the means
to improve quantitative measurements for other exons.
The applications of this technology are numerous.
Since our arrays are both scalable and sensitive at the
resolution of single exons, they fill a technological gap
between the high-throughput technologies (e.g., array
CGH by use of BAC arrays) and the high-resolution but
less scalable assays (e.g., MAPH and MLPA). Therefore,
the development of this technology opens the way for
identifying copy-number changes at high resolution in
both normal and disease states, as a research or diagnos-
tic tool, and in both large-scale and small-scale studies.
The construction of a genomewide exon array would
represent an important achievement for the analysis of
DNA-copy number in the human genome. To maintain
single-exon resolution for genomewide screening, such
an array would require at least one array element for
each of the ∼245,000 exons that have been annotated
in the human genome. On the basis of the data presented
here, that would require the design and testing of
280,000–300,000 exon-specific primer pairs and their
conversion to array elements to obtain a quantitative
working assay for every exon. Furthermore, on the basis
of current spotting technologies, multiple microarray
slides would be required to spot the entire set of exons,
resulting in increased costs per genome assayed. Al-
though this may appear to represent an enormous un-
dertaking, it must be balanced against the tremendous
760 Am. J. Hum. Genet. 76:750–762, 2005
value that such an array set could contribute to human
genetics—it would allow the identification and anno-
tation of CNPs and mutations, in normal individuals
and in disease, that have previously been undiscovered
because of limitations in the resolution of other array
CGH technologies.
In more focused approaches, exon arrays would also
facilitate positional cloning strategies of novel disease
genes in well-characterized patient collections. Given
that we have shown here a direct application of this
technology to identify copy-number changes in patient
material for several single-gene disorders, its use as a
diagnostic tool for known disease genes is evident. Fur-
thermore, it should be possible to screen many genes in
an exon array CGH format to quickly elucidate copy-
number changes for some categories of disease pheno-
types that are difficult to distinguish clinically. Exon
array CGH could also be applied to cancer genetics.
Given that there are several hundreds of genes that have
been shown to be mutated in cancer (Futreal et al.
2004), this set serves as an excellent starting point for
the construction of cancer-specific exon arrays.
It will also be possible to use our array system at this
level of resolution to answer other questions about ge-
nome biology, with the one obvious application being
chromatin immunoprecipitation (ChIP)-on-chip (Ren et
al. 2002; Weinmann et al. 2002). Given the quantifiable
signal:noise ratios we have shown here, obtaining de-
tailed maps of protein-binding sites, histone modifica-
tions, and other features, such as origins of replications
and matrix attachment regions, should also be possible
with genomic tiling-path arrays or intergenic arrays at
high resolution. This type of approach for identifying
transcription-factor binding sites onto human chro-
mosomal regions (Horak et al. 2002) and whole chro-
mosomal tiling paths (Martone et al. 2003; Cawley et
al. 2004; Euskirchen et al. 2004) has already been de-
scribed, although the proportions of sites identified that
are false-positive results or false-negative results are not
yet known. In particular, our array system is well suited
to identify low-affinity DNA-protein interactions that
give relatively poor enrichments in ChIP and small quan-
tifiable copy-number increases on arrays. We are cur-
rently extending our work in this area by generating
high-resolution genomic tiling arrays for regions of in-
terest in the human genome.
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